tiprankstipranks
Trending News
More News >
Oragenics Inc (OGEN)
:OGEN
Advertisement

Oragenics (OGEN) Price & Analysis

Compare
1,051 Followers

OGEN Stock Chart & Stats


Financials

Options Prices

Currently, No data available
---

Ownership Overview

24.75%6.90%0.49%68.31%
24.75% Insiders
0.49% Other Institutional Investors
68.31% Public Companies and
Individual Investors

OGEN FAQ

What was Oragenics Inc’s price range in the past 12 months?
Oragenics Inc lowest stock price was $1.30 and its highest was $75.60 in the past 12 months.
    What is Oragenics Inc’s market cap?
    Oragenics Inc’s market cap is $966.39K.
      When is Oragenics Inc’s upcoming earnings report date?
      The company’s upcoming earnings report date is not yet available.
      How were Oragenics Inc’s earnings last quarter?
      Currently, no data Available
      Is Oragenics Inc overvalued?
      According to Wall Street analysts Oragenics Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Oragenics Inc pay dividends?
        Oragenics Inc does not currently pay dividends.
        What is Oragenics Inc’s EPS estimate?
        Oragenics Inc’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Oragenics Inc have?
        Oragenics Inc has 715,843 shares outstanding.
          What happened to Oragenics Inc’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Oragenics Inc?
          Currently, no hedge funds are holding shares in OGEN

          Company Description

          Oragenics Inc

          Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.
          Similar Stocks
          Company
          Price & Change
          Follow
          Kazia Therapeutics
          Theriva Biologics
          Jaguar Animal Health
          Xenetic Biosciences
          Pasithea Therapeutics Corp
          Popular Stocks
          What am I Missing?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis